- Home
- MYSZ vs RNAZ Comparison
MYSZ vs RNAZ Comparison
Compare MYSZ & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYSZ
- RNAZ
- Stock Information
- Founded
- MYSZ 1999
- RNAZ 2016
- Country
- MYSZ Israel
- RNAZ United States
- Employees
- MYSZ N/A
- RNAZ N/A
- Industry
- MYSZ Computer Software: Prepackaged Software
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- MYSZ Technology
- RNAZ Health Care
- Exchange
- MYSZ Nasdaq
- RNAZ Nasdaq
- Market Cap
- MYSZ 8.2M
- RNAZ 7.2M
- IPO Year
- MYSZ N/A
- RNAZ 2021
- Fundamental
- Price
- MYSZ $1.93
- RNAZ $8.08
- Analyst Decision
- MYSZ Strong Buy
- RNAZ Strong Buy
- Analyst Count
- MYSZ 1
- RNAZ 1
- Target Price
- MYSZ $3.00
- RNAZ $20.00
- AVG Volume (30 Days)
- MYSZ 79.8K
- RNAZ 4.3M
- Earning Date
- MYSZ 03-31-2025
- RNAZ 03-31-2025
- Dividend Yield
- MYSZ N/A
- RNAZ N/A
- EPS Growth
- MYSZ N/A
- RNAZ N/A
- EPS
- MYSZ N/A
- RNAZ N/A
- Revenue
- MYSZ $9,632,000.00
- RNAZ N/A
- Revenue This Year
- MYSZ $35.62
- RNAZ N/A
- Revenue Next Year
- MYSZ $12.88
- RNAZ N/A
- P/E Ratio
- MYSZ N/A
- RNAZ N/A
- Revenue Growth
- MYSZ 43.89
- RNAZ N/A
- 52 Week Low
- MYSZ $1.05
- RNAZ $2.66
- 52 Week High
- MYSZ $9.40
- RNAZ $66.33
- Technical
- Relative Strength Index (RSI)
- MYSZ 45.77
- RNAZ 48.31
- Support Level
- MYSZ $1.67
- RNAZ $10.02
- Resistance Level
- MYSZ $1.86
- RNAZ $11.30
- Average True Range (ATR)
- MYSZ 0.16
- RNAZ 1.97
- MACD
- MYSZ 0.03
- RNAZ -0.18
- Stochastic Oscillator
- MYSZ 41.27
- RNAZ 26.75
About MYSZ My Size Inc.
My Size Inc is a USA based technology company that focuses on the development of an application that assists the consumer to accurately take the measurements of his or her own body to fit clothing without the need to try them on using a smartphone. The purpose of the company's business is to simplify the process of clothing acquisition through the Internet and to significantly reduce the rate of returns of clothing which were acquired through the internet and which are returned to the stores because of ill-fitting. The company generates its revenue through selling products to customers, and licensing cloud-enabled software subscriptions, associated software maintenance and support.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.